Identification of patients with high-risk stage II colon cancer for adjuvant therapyHak Mien Quah
Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Dis Colon Rectum 51:503-7. 2008
..The purpose of this study was to assess the prognostic significance of commonly reported clinicopathologic features of Stage II colon cancer to identify high-risk patients...
Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancerDeborah Schrag
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:3999-4005. 2002
..Nevertheless, patients may receive this treatment despite its uncertain benefit. The objective of this study was to determine the extent to which adjuvant chemotherapy is used for patients with stage II colon cancer...
- Physician visits prior to treatment for clinically localized prostate cancer
Thomas L Jang
Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York, USA
Arch Intern Med 170:440-50. 2010
..We evaluated how visits to specialists and primary care physicians (PCPs) by men with localized prostate cancer are related to treatment choice...
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical techniqueAndrew J Vickers
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Eur Urol 53:960-6. 2008
..We previously demonstrated that there is a learning curve for open radical prostatectomy. We sought to determine whether the effects of the learning curve are modified by pathologic stage...
- Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy
Ethan Basch
Department of Epidemiology and Biostatistics, and the Office of the Physician in Chief, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:5374-80. 2007
..In cancer treatment trials, clinicians traditionally report patient toxicity symptoms. Alternatively, patients could provide this information directly...
- Squamous-cell carcinoma of the anal canal: predictors of treatment outcome
Ramin Roohipour
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Dis Colon Rectum 51:147-53. 2008
..The incidence of anal canal squamous-cell carcinoma is increasing. Limited data exist on predictors of treatment failure. This study was designed to identify predictors for relapse/persistence after first-line therapy...
- Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation
Hak Mien Quah
Department of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer 113:57-64. 2008
....
- Can differences in bowel function after surgery for rectal cancer be identified by the European Organization for Research and Treatment of Cancer quality of life instrument?
Heather B Neuman
Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, New York 10021, USA
Ann Surg Oncol 14:1727-34. 2007
....
- Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis
Elena B Elkin
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 44, New York, NY 10021, USA
J Natl Cancer Inst 100:1013-21. 2008
..We compared rates of voluntary disenrollment from Medicare managed care to traditional fee-for-service Medicare among Medicare managed care enrollees with and without a cancer diagnosis...
- Squamous-cell carcinoma of the rectum: a rare but curable tumor
Caio S R Nahas
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Dis Colon Rectum 50:1393-400. 2007
..This study was designed to evaluate one institution's experience with treatment outcomes for rectal squamous-cell carcinoma...
- Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes
Ethan Basch
Health Outcomes Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, New York, NY 10065, USA
J Natl Cancer Inst 101:1624-32. 2009
..Patient self-reporting has been proposed as an additional data source, but the implications of such a shift are not understood...
- Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study
Joanne F Chou
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 116:2560-70. 2010
..However, heterogeneity in LN harvest exists. The objective of this study was to investigate the clinicopathologic factors that influence LN yield...
- The effect of clustering of outcomes on the association of procedure volume and surgical outcomes
Katherine S Panageas
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Ann Intern Med 139:658-65. 2003
..Thus, in volume-outcome studies, the degree of clustering of outcomes should be characterized because it may provide insight into variations in quality of care...
- Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection
Deborah Schrag
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Natl Cancer Inst 98:163-71. 2006
..e., hospital or surgeon) procedure volumes and patient outcomes have been demonstrated for many types of cancer operation. We performed a population-based cohort study to examine these associations for ovarian cancer resections...
- Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities
Ethan Basch
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Am Med Inform Assoc 14:264-8. 2007
..Ongoing multi-center research will evaluate the impact of this approach on clinical and administrative outcomes...
- Nodal staging score: a tool to assess adequate staging of node-negative colon cancer
Mithat Gonen
Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, 1275 York Ave, Box 44, New York, NY 10065, USA
J Clin Oncol 27:6166-71. 2009
..We sought to refine this definition by quantifying the likelihood that a pathologically node-negative patient has, indeed, no positive nodes...
- Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection
Deborah Schrag
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Surg Oncol 83:68-78; discussion 78-9. 2003
..However, the importance of surgeon case volume as a determinant of outcome has been less well studied, and it is unclear whether hospital or surgeon volume is the more powerful predictor of outcomes...
- The surgical learning curve for prostate cancer control after radical prostatectomy
Andrew J Vickers
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Natl Cancer Inst 99:1171-7. 2007
..We analyzed the surgical learning curve for prostate cancer recurrence after radical prostatectomy...
- Individualized prediction of colon cancer recurrence using a nomogram
Martin R Weiser
Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 26:380-5. 2008
..Although easy to implement, there remains significant heterogeneity within each stage grouping. In the era of multimodality treatment, a more refined tool is needed to predict recurrence...
- Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors
Geoffrey Y Ku
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer Invest 27:402-6. 2009
..We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan...
- Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort
Elena B Elkin
Health Outcomes Research Group and Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:2757-64. 2006
..Our goal was to assess the relationship between adjuvant chemotherapy use and survival in a large, population-based cohort of older women with hormone receptor (HR) -negative breast cancer...
- Identifying and measuring hospital characteristics using the SEER-Medicare data and other claims-based sources
Deborah Schrag
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Med Care 40:IV-96-103. 2002
....
- Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer
Justin E Bekelman
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 69:1456-66. 2007
..S. men...
- Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population
Deborah Schrag
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Urology 65:1118-25. 2005
..To describe the population-based patterns of care among patients with muscle-invasive bladder cancer...
- Cetuximab therapy and symptomatic hypomagnesemia
Deborah Schrag
Division of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 221, New York, NY 10011, USA
J Natl Cancer Inst 97:1221-4. 2005
..Because symptoms may be rapidly ameliorated with supplementation, we suggest that, when fatigue or hypocalcemia is encountered during cetuximab therapy, serum magnesium level be measured and repleted as necessary...
- Predicting survival after curative colectomy for cancer: individualizing colon cancer staging
Martin R Weiser
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 29:4796-802. 2011
..The purpose of this study was to extend the seventh edition of the AJCC staging system for colon cancer to incorporate additional information available from tumor registries, thereby improving prognostic accuracy...
- When you look matters: the effect of assessment schedule on progression-free survival
Katherine S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA
J Natl Cancer Inst 99:428-32. 2007
..The decision to use PFS as a primary endpoint should be made carefully when designing clinical trials, and investigators focused on a particular disease should develop consensus standards and strive for consistent surveillance intervals...
- Cancer screening among patients with advanced cancer
Camelia S Sima
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, Second Floor, New York, NY 10065, USA
JAMA 304:1584-91. 2010
..Cancer screening has been integrated into routine primary care but does not benefit patients with limited life expectancy...
- Use of surgery among elderly patients with stage IV colorectal cancer
Larissa K F Temple
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 22:3475-84. 2004
..CONCLUSION: Palliative resection of the primary tumor is often performed for elderly US patients with stage IV colorectal cancer. This practice pattern merits re-evaluation, given the improvement in the efficacy of systemic chemotherapy...
- Geographic access and the use of screening mammography
Elena B Elkin
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Med Care 48:349-56. 2010
..Inadequate mammography resources in some areas may impair access to this technology. We assessed the relationship between availability of mammography machines and the use of screening...
- Missed opportunities: racial disparities in adjuvant breast cancer treatment
Nina A Bickell
Department of Health Policy, Mount Sinai School of Medicine, New York, NY 10029, USA
J Clin Oncol 24:1357-62. 2006
..We sought to measure a racial disparity in the underuse of adjuvant treatments for early-stage breast cancer and to identify associated factors...
- Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size
Katherine S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Stat Med 26:2017-35. 2007
..By contrast, the cluster weighted GEE method is inefficient...
- Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data
Cami S Sima
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Appl Health Econ Health Policy 8:37-51. 2010
....
- Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations
Peter B Bach
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Med Care 40:IV-19-25. 2002
..Finally, they describe the available data on date of death, and explain why confidence in these measures is justified...
- Factors associated with sphincter-preserving surgery for rectal cancer at national comprehensive cancer network centers
Larissa K Temple
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Ann Surg 250:260-7. 2009
..To determine rate and predictors of sphincter-preserving surgery (SPS) for rectal cancer patients treated at specialty institutions...
- Mammography capacity and appointment wait times: barriers to breast cancer screening
Elena B Elkin
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 44, New York, NY 10021, USA
Cancer Causes Control 23:45-50. 2012
..To assess the impact of mammography capacity on appointment wait times...
- Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions
Elena B Elkin
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 44, New York, NY 10021, USA
J Clin Oncol 25:5275-80. 2007
..Shared decision making is a tenet of contemporary medicine and oncology practice. How involved elderly patients want to be in making treatment decisions and how physicians perceive patient preferences for such involvement are uncertain...
- Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection
Deborah Schrag
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Department of Medicine, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Ann Surg 236:583-92. 2002
..To compare surgeon and hospital procedure volume as predictors of outcomes for patients with rectal cancer...
- Radiation therapy facilities in the United States
Leslie K Ballas
The Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 66:1204-11. 2006
....
- A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic
Elizabeth Y Chiao
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Acquir Immune Defic Syndr 40:451-5. 2005
..The incidence of SCCA has particularly increased among men and those between 30 and 54 years of age since the introduction of HAART...
- Reliability of adverse symptom event reporting by clinicians
Thomas M Atkinson
Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave, 7th Floor, New York, NY 10022, USA
Qual Life Res 21:1159-64. 2012
..The purpose of this study was to assess the reliability of adverse event reporting of different clinicians for the same patient for the same visit...
- Patient online self-reporting of toxicity symptoms during chemotherapy
Ethan Basch
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, New York, NY 10021, USA
J Clin Oncol 23:3552-61. 2005
..Currently, clinicians collect symptom information via complex and often inefficient mechanisms, but there is growing interest in collecting outcome information directly from patients...
- How to build and interpret a nomogram for cancer prognosis
Alexia Iasonos
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, 3rd Floor, New York, NY 10021, USA
J Clin Oncol 26:1364-70. 2008
..This guide provides a nonstatistical audience with a methodological approach for building, interpreting, and using nomograms to estimate cancer prognosis or other health outcomes...
- Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
Ki Young Chung
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, H 816, New York, NY 10021, USA
J Clin Oncol 23:1803-10. 2005
....
- The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma
Nabil P Rizk
Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Am Coll Surg 198:42-50. 2004
..CONCLUSIONS: Technical complications have a large negative impact on survival after esophagogastrectomy for cancer. Strategies to optimize surgical technique and minimize complications should improve outcomes in this cancer operation...
- Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer
William P Tew
Gynecologic Medical Oncology, Medical Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Invest New Drugs 27:366-73. 2009
..To determine the maximum tolerated dose (MTD), toxicities, and suitable dose for weekly 1-h paclitaxel combined with weekly cisplatin and irinotecan to treat advanced gastrointestinal malignancies...
- Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey
Deborah Schrag
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:233-7. 2007
..As chemotherapy costs escalate, financial concerns have become relevant for more cancer patients. Yet, little is known about how oncologists communicate with patients about coping with chemotherapy treatment costs...
- An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer
Deborah Schrag
Memorila Sloan-Kettering Cancer Center, New York, NY, USA
J Clin Oncol 23:1799-802. 2005
- Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
Ethan Basch
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lancet Oncol 7:903-9. 2006
..We aimed to compare the reporting of symptom severity reported by patients and clinicians...
- Resurrecting treatment histories of dead patients: a study design that should be laid to rest
Peter B Bach
The Health Outcomes Research Group, The Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
JAMA 292:2765-70. 2004
..We conclude that studying care received prior to death can lead to invalid conclusions about the quality or type of care provided to dying patients...
- Primary care physicians who treat blacks and whites
Peter B Bach
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
N Engl J Med 351:575-84. 2004
..Further research should be conducted to address the extent to which these differences may be responsible for disparities in health care...
- Fragmentation of care for frequently hospitalized urban residents
Deborah Schrag
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, and the Department of Health Policy, Mount Sinai School of Medicine, New York, New York 10021, USA
Med Care 44:560-7. 2006
..Fragmentation across sites of care may impede efficient healthcare delivery...
- Survival of blacks and whites after a cancer diagnosis
Peter B Bach
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
JAMA 287:2106-13. 2002
..Differences in treatment, stage at presentation, and mortality from other diseases should represent the primary targets of research and interventions designed to reduce disparities in cancer outcomes...
- Adherence to surveillance among patients with superficial bladder cancer
Deborah Schrag
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Natl Cancer Inst 95:588-97. 2003
..We examined the degree to which bladder cancer patients undergo the recommended surveillance procedures and identified patient and primary care provider characteristics associated with nonadherence to these recommendations...
- Use of information resources by patients with cancer and their companions
Ethan M Basch
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 100:2476-83. 2004
..It is not clear as to whether patients and their companions differ in their patterns of content seeking...
- Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer
Justin E Bekelman
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 66:492-9. 2006
..Yet practice guidelines differ in their recommendations with regard to PORT use. We examine temporal trends in PORT use before and after the 1998 meta-analysis...
- Variations in morbidity after radical prostatectomy
Colin B Begg
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
N Engl J Med 346:1138-44. 2002
..Recent studies of surgery for cancer have demonstrated variations in outcomes among hospitals and among surgeons. We sought to examine variations in morbidity after radical prostatectomy for prostate cancer...
- The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer
Larissa K Temple
Department of Surgery, Division of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Dis Colon Rectum 48:1353-65. 2005
..Therefore, the purpose of this study was to develop an instrument to evaluate bowel function after sphincter-preserving surgery...
- The price tag on progress--chemotherapy for colorectal cancer
Deborah Schrag
Memorial Sloan-Kettering Cancer Center, New York, USA
N Engl J Med 351:317-9. 2004
- The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999
Elena B Elkin
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer 104:1149-57. 2005
..The objective of the current study was to characterize within-stage migration of tumor size in breast carcinoma, and to estimate the effect of this shift on reported breast carcinoma survival...
- Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients
Craig C Earle
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Natl Cancer Inst 98:172-80. 2006
..e., better outcomes). We examined associations between physician specialty and outcomes in a population-based cohort of elderly ovarian cancer surgery patients...
- Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma
Bruce E Hillner
Department of Internal Medicine and Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia 23298, USA
Cancer 104:1871-84. 2005
..The trade-offs between costs and survival for these two regimens have not been explored...
- Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population
Joan L Warren
Applied Research Program, National Cancer Institute, Bethesda, Maryland 20892 7344, USA
Med Care 40:IV-3-18. 2002
..The use of this database to study cancer screening, treatment, outcomes, and costs has grown in recent years...
- Potentially avoidable hospitalizations for COPD and pneumonia: the role of physician and practice characteristics
Ann S O'Malley
Center for Studying Health System Change, Washington, DC 20024 2512, USA
Med Care 45:562-70. 2007
..Hospitalizations for bacterial pneumonia and chronic obstructive pulmonary disease (COPD) occur frequently, but many are potentially avoidable...
- Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study
Jeffrey A Meyerhardt
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 22:166-74. 2004
..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain...
- Care patterns in Medicare and their implications for pay for performance
Hoangmai H Pham
Center for Studying Health System Change, Washington, DC 20024, USA
N Engl J Med 356:1130-9. 2007
....
- American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
Al B Benson
American Society of Clinical Oncology, Alexandria, VA 22314, USA
J Clin Oncol 22:3408-19. 2004
....
- American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays
Deborah Schrag
American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, Alexandria, VA 22314, USA
J Clin Oncol 22:3631-8. 2004
..Because the in vitro analytic strategy has potential importance, participation in clinical trials evaluating these technologies remains a priority...
- Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence
Jeffrey A Meyerhardt
Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Ann Intern Med 139:649-57. 2003
....
- Using propensity scores to estimate the cost-effectiveness of medical therapies
Alka Indurkhya
Department of Society, Human Development and Health, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
Stat Med 25:1561-76. 2006
..Our method is illustrated by applying it to SEER-Medicare data for muscle invasive bladder cancer to determine the most cost-effective treatment protocol...
- Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging
Seung-Yong Jeong
J Natl Cancer Inst 97:1705-6; author reply 1706-7. 2005
- Delivery of preventive services to older adults by primary care physicians
Hoangmai H Pham
Center for Studying Health System Change, Washington, DC 20024, USA
JAMA 294:473-81. 2005
..Rates of preventive services remain below national goals...
- Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment
Brenda K Edwards
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 8315, USA
J Natl Cancer Inst 97:1407-27. 2005
..This year's report updates statistics on the 15 most common cancers in the five major racial/ethnic populations in the United States for 1992-2002 and features population-based trends in cancer treatment...
- Communication and coordination: the keys to quality
Deborah Schrag
J Clin Oncol 23:6452-5. 2005
- Discussing drug costs with patients
Deborah Schrag
Clin Adv Hematol Oncol 3:525-6. 2005
- Enhancing cancer registry data to promote rational health system design
Deborah Schrag
J Natl Cancer Inst 100:378-9. 2008
- A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients
Carrie N Klabunde
Health Services and Economics Branch, Applied Research Program, National Cancer Institute, Bethesda, MD 20892 7344, USA
Ann Epidemiol 17:584-90. 2007
....
